Structurally, they look similar: MNK1 and MNK2 belong to the same enzyme family and are best known for regulating how cells make proteins. Their starring role in such a crucial cellular function has cast them into the spotlight as potential drug targets to treat nervous system disorders and chronic pain. But would it matter whether a drug targets only one of them?
In a study published in Molecular Psychiatry, researchers led by Rosalba Olga Proce, a doctoral student in the Molecular and Cellular Basis of Behavior lab led by Dr. Hanna Hornberg at the Max Delbruck Center, set out to determine whether the two enzymes—also called kinases—perform distinct functions in the brain. The team found clear differences. Mice lacking MNK1 showed less interest in newly introduced objects than controls and impaired memory of objects. By contrast, mice without MNK2 appeared normal in object recognition tests but showed enhanced interest in social contacts.
“The behavioral differences we observed suggest that each kinase has a specialized function,” says Proce. “It might be preferable to target each kinase individually when designing drugs.”








